EE513 Health Economic Evaluation Incorporating Mixture Cure Survival Analysis of Nivolumab Plus Ipilimumab for Previously Untreated Metastatic NSCLC

Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.755
https://www.valueinhealthjournal.com/article/S1098-3015(22)02959-X/fulltext
Title : EE513 Health Economic Evaluation Incorporating Mixture Cure Survival Analysis of Nivolumab Plus Ipilimumab for Previously Untreated Metastatic NSCLC
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02959-X&doi=10.1016/j.jval.2022.09.755
First page :
Section Title :
Open access? : No
Section Order : 10295
Categories :
Tags :
Regions :
ViH Article Tags :